Harrow Completes TYRVAYA Acquisition, Adding First FDA-Approved Nasal Dry Eye Spray

The Quick Take

• Harrow has completed its acquisition of TYRVAYA, the only FDA-approved nasal spray treatment for dry eye disease.
• TYRVAYA adds a drop-free, differentiated administration route to Harrow's growing ocular surface franchise.
• The deal strengthens Harrow's position in specialty ophthalmology in a high-growth chronic condition segment.

Harrow's acquisition of TYRVAYA closes a meaningful gap in the ophthalmology therapeutics market, where dry eye disease represents one of the largest and fastest-growing specialty segments in eye care. The nasal spray delivery mechanism differentiates TYRVAYA from conventional eyedrop formulations, directly addressing patient compliance challenges that have constrained market penetration for dry eye therapies for years. With tens of millions of adults affected by chronic dry eye globally, the commercial rationale for novel administration routes has drawn sustained investment from specialty pharma players seeking defensible niches within a broad and competitive ophthalmology landscape.

Harrow's move into nasal-spray dry eye therapy strengthens its competitive position against established franchises including AbbVie's RESTASIS and Bausch + Lomb's XIIDRA. For the broader ophthalmic pharmaceutical sector, this acquisition signals continued consolidation as mid-tier specialty companies pursue differentiated formulations to avoid head-to-head commodity competition. The drop-free administration angle carries particular relevance given increasing managed care scrutiny on compliance-driven patient outcomes, where formulary committees are increasingly willing to grant step-therapy exceptions for clinically differentiated delivery mechanisms that demonstrably improve adherence.

The primary forward indicator to monitor is TYRVAYA's prescription trajectory under Harrow's commercial infrastructure, since the brand is transitioning from Viatris's established sales network. Harrow's next earnings call will provide the first detailed revenue and integration-cost commentary that markets need to calibrate post-close performance expectations. The macro variable determining thesis durability is managed care reimbursement policy: if payers reclassify dry eye drugs as non-essential amid healthcare cost-containment cycles, the premium pricing that justifies a differentiated delivery mechanism could face structural erosion across subsequent formulary review periods.

Synthesized from 1 source.